Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
Moderna ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Moderna's ebitda for the twelve months ending Jun 30, 2026 was -$3.09B. For fiscal 2025 it was -$2.86B. The highest annual figure on record is $13.53B in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.86B | – |
| FY2024 | Dec 31, 2024 | -$3.76B | – |
| FY2023 | Dec 31, 2023 | -$3.62B | -137.1% |
| FY2022 | Dec 31, 2022 | $9.77B | -27.8% |
| FY2021 | Dec 31, 2021 | $13.53B | – |
| FY2020 | Dec 31, 2020 | -$732.00M | – |
| FY2019 | Dec 31, 2019 | -$515.00M | – |
| FY2018 | Dec 31, 2018 | -$388.40M | – |
| FY2017 | Dec 31, 2017 | -$248.82M | – |
| FY2016 | Dec 31, 2016 | -$208.66M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$759.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.33B | – |
| Q4 FY2025 | Dec 31, 2025 | -$791.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$209.00M | – |
| Q2 FY2025 | Jun 30, 2025 | -$851.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.01B | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.19B | -667.9% |
| Q3 FY2024 | Sep 30, 2024 | -$19.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.32B | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.23B | – |
| Q4 FY2023 | Dec 31, 2023 | $209.00M | -87.4% |
| Q3 FY2023 | Sep 30, 2023 | -$1.77B | -238.1% |
| Q2 FY2023 | Jun 30, 2023 | -$1.78B | -170.4% |
| Q1 FY2023 | Mar 31, 2023 | -$288.00M | -106.7% |
| Q4 FY2022 | Dec 31, 2022 | $1.66B | -69.8% |
| Q3 FY2022 | Sep 30, 2022 | $1.28B | -64.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.52B | -19.4% |
| Q1 FY2022 | Mar 31, 2022 | $4.31B | +236.1% |
| Q4 FY2021 | Dec 31, 2021 | $5.49B | – |
| Q3 FY2021 | Sep 30, 2021 | $3.63B | – |
| Q2 FY2021 | Jun 30, 2021 | $3.13B | – |
| Q1 FY2021 | Mar 31, 2021 | $1.28B | – |
| Q4 FY2020 | Dec 31, 2020 | -$268.00M | – |
| Q3 FY2020 | Sep 30, 2020 | -$227.00M | – |
| Q2 FY2020 | Jun 30, 2020 | -$114.00M | – |
| Q1 FY2020 | Mar 31, 2020 | -$124.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$121.60M | – |
| Q3 FY2019 | Sep 30, 2019 | -$123.46M | – |
| Q2 FY2019 | Jun 30, 2019 | -$136.21M | – |
| Q1 FY2019 | Mar 31, 2019 | -$134.33M | – |
| Q4 FY2018 | Dec 31, 2018 | -$145.68M | – |
| Q3 FY2018 | Sep 30, 2018 | -$79.32M | – |
| Q2 FY2018 | Jun 30, 2018 | -$91.12M | – |
| Q1 FY2018 | Mar 31, 2018 | -$72.25M | – |
See a number that looks wrong?